RepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private Placement

Dec 25, 2015

RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin

Dec 18, 2015

RepliCel Life Sciences Announces Leadership Transition

Dec 17, 2015

RepliCel Life Sciences Inc. Announces Closing of First Tranche of Private Placement

Nov 24, 2015

RepliCel Executives to Present at 9th World Congress for Hair Research in Miami

Nov 13, 2015

Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE

Nov 12, 2015

Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference

Nov 10, 2015

RepliCel Selected as One of This Year’s Top 20 Public Canadian Technology Companies

Nov 5, 2015

Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone

Oct 27, 2015

Resverlogix Corp. Selected to Present at Cavendish Global Health Impact Forum

Oct 23, 2015

First Participants Enrolled in RepliCel’s Phase 1 Clinical Trial of its RCS-01 Dermatology Injectable

Oct 21, 2015

Industry Leader Geoff MacKay Joins RepliCel Life Sciences’ Board of Directors

Oct 16, 2015

RepliCel Announces October Presentation and Partnering Meeting Schedule

Oct 9, 2015

Resverlogix Provides Research and Development Update in New York City

Sep 30, 2015

Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases

Sep 25, 2015

RepliCel Presenting at Two Upcoming Investment and Partnering Forums

Sep 24, 2015

RepliCel Life Sciences Announces Initiation of Clinical Site and Participant Recruitment for European Skin Aging Study

Sep 16, 2015

Resverlogix Presents at the Rodman & Renshaw 17th Annual Global Investment Conference

Sep 10, 2015